Voriconazole pharmacokinetics in liver transplant recipients.
about
Impact of CYP2C19 Genotype and Liver Function on Voriconazole Pharmacokinetics in Renal Transplant Recipients.Bioavailability and population pharmacokinetics of voriconazole in lung transplant recipients.Variability of voriconazole plasma concentrations after allogeneic hematopoietic stem cell transplantation: impact of cytochrome p450 polymorphisms and comedications on initial and subsequent trough levelsTargeted versus universal antifungal prophylaxis among liver transplant recipientsProspective, observational study of voriconazole therapeutic drug monitoring among lung transplant recipients receiving prophylaxis: factors impacting levels of and associations between serum troughs, efficacy, and toxicityDiagnostic and therapeutic challenges in a liver transplant recipient with central nervous system invasive aspergillosis.Plasma Voriconazole Estimation by HPLC.Voriconazole therapeutic drug monitoring: retrospective cohort study of the relationship to clinical outcomes and adverse events.Pharmacogenomics of the triazole antifungal agent voriconazole.Efficacy and cost-effectiveness of voriconazole prophylaxis for prevention of invasive aspergillosis in high-risk liver transplant recipients.Pharmacokinetic and Pharmacodynamic Properties of Oral Voriconazole in Patients with Invasive Fungal Infections.Population pharmacokinetic evaluation with external validation and Bayesian estimator of voriconazole in liver transplant recipients.Observational Study of Associations between Voriconazole Therapeutic Drug Monitoring, Toxicity, and Outcome in Liver Transplant Patients.Effect of cytochrome P450 2C19 genotype on voriconazole exposure in cystic fibrosis lung transplant patients
P2860
Q30491969-C2E385B1-0239-484C-8E04-F22E2CE32606Q34150943-1154D587-8FC3-427B-B79F-440F796EE829Q35169112-407D744E-2FBE-4CD9-B557-1948F8F35E38Q35194743-B98C4FA5-2091-43EB-9DA5-548DD6140319Q35941502-FE428150-5C0C-4092-AEA1-D93B3DC75A7FQ36094956-26A97488-9DF7-485E-BAA2-40D8ED5ECE0DQ36764126-D811D02E-C03E-4A20-8EC1-AD532D5B450BQ36849416-88497E12-CF17-4BDA-8E6B-C0F2083EC7EAQ37892536-80FFFD27-32E5-4408-A92F-3A31CAB84AB2Q40377329-BDADA06A-64FC-4181-8CE9-4B4AA12FBA49Q40982014-F9AB6074-3DB9-4536-9591-79BA6448FBF0Q44334907-5A4C5860-9A44-47A8-9942-86340DC294D5Q50035124-E22FC9DE-65A6-4404-B86D-C7AB413E966FQ57611765-D38E858A-FE6D-4ACE-9FA8-58C18A343449
P2860
Voriconazole pharmacokinetics in liver transplant recipients.
description
2009 nî lūn-bûn
@nan
2009 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Voriconazole pharmacokinetics in liver transplant recipients.
@ast
Voriconazole pharmacokinetics in liver transplant recipients.
@en
type
label
Voriconazole pharmacokinetics in liver transplant recipients.
@ast
Voriconazole pharmacokinetics in liver transplant recipients.
@en
prefLabel
Voriconazole pharmacokinetics in liver transplant recipients.
@ast
Voriconazole pharmacokinetics in liver transplant recipients.
@en
P2093
P2860
P356
P1476
Voriconazole pharmacokinetics in liver transplant recipients
@en
P2093
B Capitano
H J Johnson
P K Linden
R Venkataramanan
P2860
P304
P356
10.1128/AAC.00429-09
P407
P577
2009-11-23T00:00:00Z